Alirocumab after Acute Coronary Syndrome

Nick S.R. Lan, Bu B. Yeap, P. Gerry Fegan

Research output: Contribution to journalLetter

Abstract

To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

Original languageEnglish
Pages (from-to)2075-2076
Number of pages2
JournalThe New England Journal of Medicine
Volume380
Issue number21
DOIs
Publication statusPublished - 23 May 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Acute Coronary Syndrome
Therapeutics
Cholesterol
Guidelines
alirocumab
Ezetimibe

Cite this

Lan, Nick S.R. ; Yeap, Bu B. ; Fegan, P. Gerry. / Alirocumab after Acute Coronary Syndrome. In: The New England Journal of Medicine. 2019 ; Vol. 380, No. 21. pp. 2075-2076.
@article{7494d8cf4b7d4cbb82541e07cc4190ba,
title = "Alirocumab after Acute Coronary Syndrome",
abstract = "To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3{\%} of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .",
author = "Lan, {Nick S.R.} and Yeap, {Bu B.} and Fegan, {P. Gerry}",
year = "2019",
month = "5",
day = "23",
doi = "10.1056/NEJMc1902955",
language = "English",
volume = "380",
pages = "2075--2076",
journal = "The New England Journal of Medicine",
issn = "0028-4793",
publisher = "MASSACHUSETTS MEDICAL SOC",
number = "21",

}

Alirocumab after Acute Coronary Syndrome. / Lan, Nick S.R.; Yeap, Bu B.; Fegan, P. Gerry.

In: The New England Journal of Medicine, Vol. 380, No. 21, 23.05.2019, p. 2075-2076.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Alirocumab after Acute Coronary Syndrome

AU - Lan, Nick S.R.

AU - Yeap, Bu B.

AU - Fegan, P. Gerry

PY - 2019/5/23

Y1 - 2019/5/23

N2 - To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

AB - To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

UR - http://www.scopus.com/inward/record.url?scp=85066493960&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1902955

DO - 10.1056/NEJMc1902955

M3 - Letter

VL - 380

SP - 2075

EP - 2076

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -